Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(3.93)
# 517
Out of 4,829 analysts
228
Total ratings
33.82%
Success rate
14.81%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Maintains: Overweight | $113 → $112 | $44.23 | +153.22% | 19 | May 7, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $23 | $18.75 | +22.67% | 7 | May 7, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $163 → $81 | $36.27 | +123.33% | 16 | May 7, 2025 | |
| TSHA Taysha Gene Therapies | Reiterates: Overweight | $7 | $2.13 | +228.64% | 16 | Apr 28, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Overweight | $67 → $123 | $76.76 | +60.24% | 6 | Mar 27, 2025 | |
| XFOR X4 Pharmaceuticals | Reiterates: Overweight | $90 | $3.37 | +2,570.62% | 4 | Mar 26, 2025 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $30 | $6.34 | +373.19% | 5 | Mar 20, 2025 | |
| MREO Mereo BioPharma Group | Reiterates: Overweight | $7 | $2.41 | +190.46% | 10 | Mar 18, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $99 → $132 | $44.24 | +198.37% | 8 | Mar 18, 2025 | |
| ZVRA Zevra Therapeutics | Reiterates: Overweight | $25 | $7.87 | +217.66% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $19.98 | +25.13% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $118 | $35.11 | +236.09% | 18 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 | $31.70 | +13.56% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $18.33 | +265.52% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $5.99 | +250.88% | 7 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $29 | $7.71 | +276.38% | 13 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $2.79 | +509.32% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $0.80 | +902.26% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $58 | $12.79 | +353.48% | 9 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $2.46 | +347.15% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $5.27 | +241.56% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $1.81 | +673.48% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.19 | +992.44% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.36 | - | 3 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.48 | +1,318.92% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $0.44 | +1,263.64% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $1.53 | +1,207.19% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $2.95 | +679.66% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $1.17 | +77,153.22% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $41 | $0.73 | +5,516.44% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $2.75 | +14,471.95% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $0.77 | +10,891.85% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3,500 | $0.39 | +893,669.15% | 1 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.49 | +2,673.50% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $1.26 | +3,471.43% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $0.67 | +1,541.79% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.17 | +5,028.21% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.13 | +7,847.02% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $1.24 | +203,125.81% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.52 | +30,907.75% | 1 | Jan 9, 2020 |
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $113 → $112
Current: $44.23
Upside: +153.22%
Rigel Pharmaceuticals
May 7, 2025
Maintains: Neutral
Price Target: $20 → $23
Current: $18.75
Upside: +22.67%
Sarepta Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $36.27
Upside: +123.33%
Taysha Gene Therapies
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $2.13
Upside: +228.64%
Soleno Therapeutics
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $76.76
Upside: +60.24%
X4 Pharmaceuticals
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $3.37
Upside: +2,570.62%
Capricor Therapeutics
Mar 20, 2025
Reiterates: Overweight
Price Target: $30
Current: $6.34
Upside: +373.19%
Mereo BioPharma Group
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $2.41
Upside: +190.46%
Disc Medicine
Mar 18, 2025
Maintains: Overweight
Price Target: $99 → $132
Current: $44.24
Upside: +198.37%
Zevra Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: $25
Current: $7.87
Upside: +217.66%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $19.98
Upside: +25.13%
Feb 26, 2025
Reiterates: Overweight
Price Target: $118
Current: $35.11
Upside: +236.09%
Feb 26, 2025
Reiterates: Neutral
Price Target: $36
Current: $31.70
Upside: +13.56%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $18.33
Upside: +265.52%
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $5.99
Upside: +250.88%
Jan 2, 2025
Reiterates: Overweight
Price Target: $29
Current: $7.71
Upside: +276.38%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $2.79
Upside: +509.32%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $0.80
Upside: +902.26%
Dec 10, 2024
Maintains: Overweight
Price Target: $28 → $58
Current: $12.79
Upside: +353.48%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.46
Upside: +347.15%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $5.27
Upside: +241.56%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $1.81
Upside: +673.48%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $1.19
Upside: +992.44%
Sep 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.36
Upside: -
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.48
Upside: +1,318.92%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $0.44
Upside: +1,263.64%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $1.53
Upside: +1,207.19%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $2.95
Upside: +679.66%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $1.17
Upside: +77,153.22%
Aug 10, 2023
Maintains: Overweight
Price Target: $44 → $41
Current: $0.73
Upside: +5,516.44%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $2.75
Upside: +14,471.95%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $0.77
Upside: +10,891.85%
Feb 28, 2022
Initiates: Overweight
Price Target: $3,500
Current: $0.39
Upside: +893,669.15%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.49
Upside: +2,673.50%
May 26, 2021
Initiates: Overweight
Price Target: $45
Current: $1.26
Upside: +3,471.43%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $0.67
Upside: +1,541.79%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.17
Upside: +5,028.21%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.13
Upside: +7,847.02%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $1.24
Upside: +203,125.81%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.52
Upside: +30,907.75%